Diagnostic radio-labeled polysaccharide derivatives

Claim 2

A metal-binding intermediate compound for preparing a radiopharmaceutical for diagnosing blood clots comprising: (a) a water-soluble polysaccharide moiety having an average of at least 0.25 anionic groups per monosaccharide unit, and (b) at least one chelating group derived from the group consisting of amino acids, substituted cyclic acid anhydrides, and carbon disulfide.

Claim 3

The metal-binding intermediate compound according to claim 1 wherein said polysaccharide moiety is derived from the group consisting of homopolysaccharides and heteropolysaccharides.

Claim 4

The metal-binding intermediate compound according to claim 2 wherein said heteropolysaccharides are selected from the group consisting of chondroitin sulfates A and C, dermatan sulfate, keratan sulfates I and II, heparan sulfate, and heparin.

Claim 5

The metal-binding intermediate compound according to claim 2 wherein said homopolysaccharide is selected from the group consisting of dextran sulfates.

Claim 6

The metal-binding intermediate compound according to claim 1 wherein the water-soluble polysaccharide moiety is derived from heparin by desulfation.

Claim 7

The metal-binding intermediate compound according to claim 1 wherein the chelating group is derived from the group consisting of diethylenetriaminepentaacetic acid, ethylenediaminetetraacetic acid, cyclohexyldiamine tetraacetic acid, diethylenetriaminepentamethylene phosphonic acid, carbon disulfide, and substituted succinic anhydrides.

Claim 8

A radiopharmaceutical compound for diagnosing blood clots formed by the a reaction of: (a) a metal-binding intermediate compound comprising: (1) a water-soluble polysaccharide moiety having an average of at least 0.25 anionic groups per monosaccharide unit, and (2) at least one chelating group, and (b) a radioactive tracer metal compound.

Claim 9

A radiopharmaceutical compound for diagnosing blood clots formed by the a reaction of: (a) a metal-binding intermediate compound comprising: (1) a water-soluble polysaccharide moiety having an average of at least 0.25 anionic groups per monosaccharide unit, and (2) at least one chelating group, and (b) a radioactive tracer metal compound.

Claim 10

The radiopharmaceutical compound according to claim 7 wherein the radioactive tracer metal compound is a 111 In, 99m Tc, 51 Cr or 68 Ga compound.

Claim 11

The radiopharmaceutical compound according to claim 7 wherein the radioactive tracer metal compound is a 111 In compound.

Claim 12

The radiopharmaceutical compound according to claim 7 wherein the radioactive tracer metal compound is a 99m Tc compound.

Claim 13

A method for diagnosing and locating a formed or forming blood clot in a mammal comprising the steps: (a) injecting intravenously said mammal with less than about 1.0 mg/kg of the radiopharmaceutical compound, according to claim 8, in a physiologically acceptable medium, and (b) examining said mammal with γ-imaging or scintillographic equipment.

Claim 14

A metal-binding heparinoid intermediate compound for diagnosing blood clots comprising a reaction product of: (a) a heparin amine moiety, formed by the removal of 10 to 100% of the N-sulfate groups of heparin salt, and (b) at least one chelating group derived from the group consisting of amino acids, substituted cyclic acid anhydrides, and carbon disulfide.

Claim 15

A metal-binding heparinoid intermediate compound for diagnosing blood clots comprising a reaction product of: (a) a heparin amine moiety, formed by the removal of 10 to 100% of the N-sulfate groups of heparin salt, and (b) at least one chelating group derived from the group consisting of amino acids, substituted cyclic acid anhydrides, and carbon disulfide.

Claim 16

The metal-binding heparinoid intermediate compound according to claim 12 wherein the heparin amine moiety is formed by the removal of 30 to 70% of the N-sulfate groups on the heparin salt.

Claim 17

The metal-binding heparinoid intermediate compound according to claim 12 wherein the heparin amine moiety is formed by the removal of 40 to 60% of the N-sulfate groups on the heparin salt.

Claim 18

The metal-binding heparinoid intermediate compound according to claim 12 wherein the chelating group is derived from the group consisting of diethylenetriaminepentaacetic acid, ethylenediaminetetraacetic acid, cyclohexyldiamine tetraacetic acid, diethylenetriaminepentamethylenephosphonic acid, carbon disulfide, and substituted succinic anhydrides.

Claim 19

The metal-binding heparinoid intermediate compound according to claim 12 wherein up to 100% of the N-sulfate groups on the heparin salt have been removed and wherein the chelating group is derived from DTPA.

Claim 20

The metal-binding heparinoid intermediate compound according to claim 12 wherein up to 100% of the N-sulfate groups on the heparin salt have been removed and wherein the chelating group is derived from CS 2 .

Claim 21

A radio-labeled heparinoid compound for diagnosing blood clots formed by the reaction of (a) a metal binding heparinoid intermediate compound comprising: (1) a heparin amine moiety, formed by the removal of 10 to 100% of the N-sulfate groups of heparin salt, and (2) at least one chelating group, and (b) a radioactive tracer metal compound.

Claim 22

A radio-labeled heparinoid compound for diagnosing blood clots formed by the reaction of (a) a metal binding heparinoid intermediate compound comprising: (1) a heparin amine moiety, formed by the removal of 10 to 100% of the N-sulfate groups of heparin salt, and (2) at least one chelating group, and (b) a radioactive tracer metal compound.

Claim 23

The radio-labeled heparinoid compound according to claim 18 wherein the radioactive tracer metal compound is a 111 In, 99m Tc, 51 Cr or 68 Ga compound.

Claim 24

The radio-labeled heparinoid compound according to claim 18 wherein the radioactive tracer metal compound is a reduced pertechnetate compound.

Claim 25

A metal-binding heparinoid compound having the formula: ##STR24## wherein: a and b are numbers having a value from about 5 to 50 and b is less than or equal to a; R is the residue of heparin salt devoid its NHSO 3 - groups; n is a number having a value of 1 to 50; ##STR25## K is a coordinating ligand selected from the groups consisting of: (a) (CH 2 ) p N--R 1 ) 2 in which: each R 1 is independently selected from the group consisting of (1) hydrogen, (2) --CH 2 ) p Y, in which Y is ##STR26## (3) --CH 2 ) p N--R 1 ) 2 , and p is an integer of 1 to 3, and M is hydrogen, an alkali metal ion, ammonium ion or a lower alkyl group having 1 to 4 carbon atoms, with the proviso that K contains no more than 4 nitrogen atoms and no nitrogen atom in K has more than one --CH 2 ) p Y groups in which Y is --H or --CH 3 ; (b) ##STR27## in which: p and R 1 are as defined in (a), q is 0 or 1 to 3, and R 2 is a divalent group having 2 to 6 carbon atoms, of which one carbon atoms can be replaced by --O--, --S--, or --NH--, which atoms are necessary in order to form a ring with --CH--CH 2 ) q CH--, the ring having 5 to 8 nuclear atoms that can be saturated or unsaturated and optionally substituted by --CH 2 ) q Y groups in which Y is as defined in (a) and q is 0 or 1 to 4; (c) ##STR28## in which: t is an integer of 0 or 1, p is an integer of 1 to 3, R 3 is a group selected from --OH, --SH, ##STR29## (d) [(CH 2 ) r O] s R 4 in which: r and s are independently integers of 1 to 4, and R 4 is hydrogen or lower alkyl of 1 to 4 carbon atoms; (e) ##STR30## in which: r, p, and t are integers of 1 to 4, 1 to 3, and 0 or 1 respectively, Z is --O--, --S--, or --NH--, and R 5 is a lower alkyl group having 1 to 4 carbon atoms; (f) ##STR31## in which: R 6 is alkylene or alkenylene having 1 to 4 carbon atoms, M is as defined in (a), and A is ##STR32## in which R 4 and Z are as defined in (d) and (e) respectively; and (g) ##STR33## in which: R 7 is --CH 2 ) q Y in which q is 0 or 1 to 4 and Y and M are as defined in (a).

Claim 26

A metal-binding heparinoid compound having the formula: ##STR24## wherein: a and b are numbers having a value from about 5 to 50 and b is less than or equal to a; R is the residue of heparin salt devoid its NHSO 3 - groups; n is a number having a value of 1 to 50; ##STR25## K is a coordinating ligand selected from the groups consisting of: (a) (CH 2 ) p N--R 1 ) 2 in which: each R 1 is independently selected from the group consisting of (1) hydrogen, (2) --CH 2 ) p Y, in which Y is ##STR26## (3) --CH 2 ) p N--R 1 ) 2 , and p is an integer of 1 to 3, and M is hydrogen, an alkali metal ion, ammonium ion or a lower alkyl group having 1 to 4 carbon atoms, with the proviso that K contains no more than 4 nitrogen atoms and no nitrogen atom in K has more than one --CH 2 ) p Y groups in which Y is --H or --CH 3 ; (b) ##STR27## in which: p and R 1 are as defined in (a), q is 0 or 1 to 3, and R 2 is a divalent group having 2 to 6 carbon atoms, of which one carbon atoms can be replaced by --O--, --S--, or --NH--, which atoms are necessary in order to form a ring with --CH--CH 2 ) q CH--, the ring having 5 to 8 nuclear atoms that can be saturated or unsaturated and optionally substituted by --CH 2 ) q Y groups in which Y is as defined in (a) and q is 0 or 1 to 4; (c) ##STR28## in which: t is an integer of 0 or 1, p is an integer of 1 to 3, R 3 is a group selected from --OH, --SH, ##STR29## (d) [(CH 2 ) r O] s R 4 in which: r and s are independently integers of 1 to 4, and R 4 is hydrogen or lower alkyl of 1 to 4 carbon atoms; (e) ##STR30## in which: r, p, and t are integers of 1 to 4, 1 to 3, and 0 or 1 respectively, Z is --O--, --S--, or --NH--, and R 5 is a lower alkyl group having 1 to 4 carbon atoms; (f) ##STR31## in which: R 6 is alkylene or alkenylene having 1 to 4 carbon atoms, M is as defined in (a), and A is ##STR32## in which R 4 and Z are as defined in (d) and (e) respectively; and (g) ##STR33## in which: R 7 is --CH 2 ) q Y in which q is 0 or 1 to 4 and Y and M are as defined in (a).

Claim 27

A radio-labeled heparinoid compound comprising a reaction product of the metal-binding heparinoid compound according to claim 21 and a radioactive metal compound.

Claim 28

A method for diagnosing and locating a formed or forming blood clot in the vascular system of a mammal comprising the steps: (a) injecting intravenously said mammal with less than about 1.0 mg/kg of the radio-labeled heparinoid compound, according to claim 22, in a physiologically acceptable medium, and (b) examining said mammal with γ-imaging or scintillographic equipment.

Claim 29

A compound comprising: (a) a water-soluble polysaccharide moiety having an average of at least 0.25 anionic group per monosaccharide unit, and (b) at least one chelating group derived from the group consisting of amino acids, substituted cyclic acid anhydrides, and carbon disulfide.

Claim 30

A compound comprising: (a) a water-soluble polysaccharide moiety having an average of at least 0.25 anionic group per monosaccharide unit, and (b) at least one chelating group derived from the group consisting of amino acids, substituted cyclic acid anhydrides, and carbon disulfide.

Claim 31

A compound comprising the reaction product of: (a) a compound comprising: (1) a water-soluble polysaccharide moiety having an average of at least 0.25 anionic group per monosaccharide unit, and (2) at least one chelating group, and (b) a radioactive tracer metal compound.

Claim 32

A compound comprising the reaction product of: (a) a compound comprising: (1) a water-soluble polysaccharide moiety having an average of at least 0.25 anionic group per monosaccharide unit, and (2) at least one chelating group, and (b) a radioactive tracer metal compound.